{"blog": [], "keywords": [{"value": "Editorials", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Mylan Inc", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "5", "is_major": "Y"}, {"value": "Medical Devices", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Epinephrine (Drug)", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "Klobuchar, Amy", "name": "persons", "rank": "8", "is_major": "N"}, {"value": "Federal Trade Commission", "name": "organizations", "rank": "9", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/08/25/opinion/another-drug-pricing-ripoff.html", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "type_of_material": "Editorial", "multimedia": [{"url": "images/2016/08/25/opinion/25thu3web/25thu3web-thumbWide.jpg", "legacy": {"wide": "images/2016/08/25/opinion/25thu3web/25thu3web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/08/25/opinion/25thu3web/25thu3web-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/25/opinion/25thu3web/25thu3web-articleLarge.jpg", "xlargeheight": "387", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 387}, {"url": "images/2016/08/25/opinion/25thu3web/25thu3web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/08/25/opinion/25thu3web/25thu3web-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Opinion", "word_count": "541", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The rapid price increase in the EpiPen is an extreme example of the common practice of raising prices solely to reap higher profits.", "pub_date": "2016-08-25T04:00:00+0000", "news_desk": "Editorial", "headline": {"kicker": "Editorial", "print_headline": "Another Drug Pricing Ripoff", "main": "Another Drug Pricing Ripoff", "content_kicker": "Editorial"}, "print_page": "18", "snippet": "The rapid price increase in the EpiPen is an extreme example of the common practice of raising prices solely to reap higher profits....", "_id": "57be9c7d95d0e021d798281f", "slideshow_credits": null, "abstract": "Editorial excoriates Mylan Pharmaceuticals for raising price of EpiPen, which can save people from deadly allergic reactions, from $100 in 2007 to nearly $600 in 2016; argues one reason prices have skyrocketed is practice of companies paying competitors to delay release of generic drugs; calls on Congress to take closer look at pharmaceutical industry and find possible legislative remedies."}